Last $706.11 MXN
Change Today 0.00 / 0.00%
Volume 0.0
ABT* On Other Exchanges
SIX Swiss Ex
Sao Paulo
As of 4:09 PM 02/24/15 All times are local (Market data is delayed by at least 15 minutes).

abbott laboratories (ABT*) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/24/15 - $706.11
52 Week Low
04/9/14 - $489.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ABBOTT LABORATORIES (ABT*)

abbott laboratories (ABT*) Details

Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome, intrahepatic cholestasis or depressive symptoms, gynecological disorders, dyslipidemia, hypertension, hypothyroidism, pain, fever, and inflammation; and regulates physiological rhythm of the colon, as well as provides hormone replacement therapy and anti-infective and influenza vaccines. The company’s Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents. Its Nutritional Products segment offers pediatric and adult nutritional products, such as various forms of prepared infant and follow-on formula. The company’s Vascular Products segment provides coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular diseases. Abbott Laboratories also offers blood glucose and glucose monitoring systems, test strips, and data management software and accessories for people with diabetes; and medical devices for the eye, such as cataract surgery, LASIK surgery, and contact lens care and dry eye products. The company primarily serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. It has strategic alliance with Fonterra Co-operative Group Ltd. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

77,000 Employees
Last Reported Date: 01/29/15
Founded in 1888

abbott laboratories (ABT*) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.9M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $969.7K
Executive Vice President, General Counsel and...
Total Annual Compensation: $650.0K
Executive Vice President of Diagnostic Produc...
Total Annual Compensation: $614.6K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $629.5K
Compensation as of Fiscal Year 2013.

abbott laboratories (ABT*) Key Developments

Abbott Laboratories to Distribute an Unchanged Quarterly Dividend on May 15, 2015

Abbott Laboratories announced that it will distribute an unchanged quarterly dividend of $0.24 per share on May 15, 2015 to holders of record on April 15, 2015 with an ex-dividend date of April 13, 2015.

Abbott Unveils Two New Intraocular Lenses for People with Cataracts in US

Abbott has announced the US launch of two new Tecnis Multifocal intraocular lenses, or IOLs, for people with cataracts. An IOL is an artificial lens placed in a person's eye to restore vision after a cataract has been removed. While traditional monofocal IOLs are designed to restore far or distance vision, multifocal IOLs provide quality vision at multiple distances and reduce or eliminate the need for glasses. The new lenses approved by the FDA are known as TECNIS Multifocal +2.75D and +3.25D IOLs. Along with the available TECNIS Multifocal +4.0D IOL, all of the TECNIS Multifocal IOLs provide excellent vision at near, intermediate and far distances, while each "lens power" version provides enhanced vision at a distinct distance. The new TECNIS Multifocal IOLs provide people with cataracts options to customize their treatment based on their personal vision needs and lifestyle. The TECNIS Multifocal +4.0D is suited for people favoring near vision-related activities, such as reading a book. The TECNIS Multifocal +3.25D IOL is suited for people who favor activities at longer reading distances, such as reading a hand-held device like a tablet. The TECNIS Multifocal +2.75D IOL is suited for people who favor activities done with intermediate vision, such as reading labels while grocery shopping.

Insulet Extends Exclusive Agreement with Abbott Laboratories for Blood Glucose Monitoring

Insulet Corporation announced that it has extended its ongoing exclusive agreement with Abbott Laboratories to continue integration of the Abbott FreeStyle® blood glucose (BG) monitoring technology with Insulet's OmniPod System. The FreeStyle blood glucose meter is built into the OmniPod hand-held Personal Diabetes Manager (PDM), eliminating the need to carry and manage a separate meter or transfer BG results from device to device.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABT*:MM $706.11 MXN 0.00

ABT* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $60.52 USD -0.10
Actavis plc $289.78 USD -0.62
Danaher Corp $87.81 USD +0.59
Eli Lilly & Co $70.03 USD -0.33
Teva Pharmaceutical Industries Ltd $56.49 USD -0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation ABT* Industry Range
Price/Earnings 42.1x
Price/Sales 3.6x
Price/Book 3.1x
Price/Cash Flow 25.1x
TEV/Sales 2.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBOTT LABORATORIES, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at